Research Participation
Client Portal
Talk to an expert
Go Back

AbbVie price target raised to $220 from $212 at Piper Sandler

Piper Sandler analyst Christopher Raymond raised the firm’s price target on AbbVie (ABBV) to $220 from $212 and keeps an Overweight rating on the shares. The firm is increasing its Skyrizi and Rinvoq estimates and price target following insights from proprietary survey data with its partners at Spherix, showing meaningful tailwinds for both products in the IBD space.

Source: https://markets.businessinsider.com/news/stocks/abbvie-price-target-raised-to-220-from-212-at-piper-sandler-1034147143

Sign up for alerts, market insights and exclusive content in your inbox.

Related Articles

view all news and media
Gastroenterology   •   Press Release

Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June

Dermatology   •   Press Release

Long-Term Psoriatic Arthritis Data for AbbVie’s Skyrizi Likely to Impact Future IL-23 Preference, Spherix Global Insights Reports

Gastroenterology   •   Media Coverage

The Oral GLP-1 Tracker: Novo’s oral Wegovy hits 3M prescription milestone as Lilly’s Foundayo chugs along in early launch

Hematology   •   Press Release

Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success